Variable levels of CD38 expression have been detected in approximately 80% of angioimmunoblastic T-cell lymphoma (AITL) and 60% of peripheral T-cell lymphoma, not otherwise (PTCL-NOS), thus providing a rationale for novel treatment with anti-CD38 antibodies [79]. This evidence concerns the gene CD38 and mature T-cell and NK-cell non-Hodgkin lymphoma.